This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christodoulopoulos, G. Articles by Panasci, L. C. Search for Related Content PubMed PubMed Citation Articles by Christodoulopoulos, G. Articles by Panasci, L. C.

Chlorambucil Induction of HsRad51 in B-Cell Chronic Lymphocytic Leukemia¹

Lady Davis Institute for Medical Research, The Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, H3T 1E2 Canada [G. C., A. M., H. S., L. C. P.], and Yale University, Department of Genetics, School of Medicine, New Haven, Connecticut 06520-8005 [E. G., C. R.]

Our previous studies with B-cell chronic lymphocytic leukemia (B-CLL) have suggested that one of the mechanisms of nitrogen mustard (NM) drug resistance is increased repair of drug-induced damage. We have postulated that recombination may play a crucial role in this process. The human homologue of Rad51, (HsRad51), has homology to the RecA protein in Escherichia coli, which is implicated in recombination repair and induction of DNA repair enzymes. In this report, we have examined the expression and distribution of HsRad51 protein in lymphocytes from patients with B-CLL to see whether the expression of HsRad51 is associated with NM damage to the malignant B lymphocytes, specifically chlorambucil (CLB), which is the standard alkylating agent used to treat patients with B-CLL. We have analyzed the intracellular distribution of HsRad51 protein in these lymphocytes before and after treatment with CLB by immunofluorescence. In vitro CLB treatment induces Rad51 expression, as measured by increased immunopositive staining in all CLL samples. In the CLB-resistant CLL lymphocytes, there was a linear correlation between induction of Rad51 protein at 5.4 µM CLB and the in vitro LD₅₀ dose of CLB. Surprisingly, although it has been reported that Rad51 is induced in S phase and only 10% of cells from cell lines expressed positive immunostaining for Rad51, our CLL lymphocytes, which were not subjected to in vitro drug exposure, were 90% positive for Rad51, despite their nonproliferative state, which suggests that there is chronic activation of the protein. Our results suggest that CLB activates HsRad51-directed recombination repair and that this process may be important in NM drug-induced cytotoxicity.

This article has been cited by other articles:

				E. Willmore, S. L. Elliott, T. Mainou-Fowler, G. P. Summerfield, G. H. Jackson, F. O'Neill, C. Lowe, A. Carter, R. Harris, A. R. Pettitt, et al. DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia Clin. Cancer Res., June 15, 2008; 14(12): 3984 - 3992. [Abstract] [Full Text] [PDF]

				J. Nomme, Y. Takizawa, S. F. Martinez, A. Renodon-Corniere, F. Fleury, P. Weigel, K.-i. Yamamoto, H. Kurumizaka, and M. Takahashi Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein. Genes Cells, May 1, 2008; 13(5): 471 - 481. [Abstract] [Full Text] [PDF]

				L. Amrein, M. Loignon, A.-C. Goulet, M. Dunn, B. Jean-Claude, R. Aloyz, and L. Panasci Chlorambucil Cytotoxicity in Malignant B Lymphocytes Is Synergistically Increased by 2-(Morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-Mediated Inhibition of DNA Double-Strand Break Repair via Inhibition of DNA-Dependent Protein Kinase J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 848 - 855. [Abstract] [Full Text] [PDF]

				M. A. Cerone, J. A. Londono-Vallejo, and C. Autexier Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol. Cancer Ther., July 1, 2006; 5(7): 1669 - 1675. [Abstract] [Full Text] [PDF]

				R. J. Ward and C. Autexier Pharmacological Telomerase Inhibition Can Sensitize Drug-Resistant and Drug-Sensitive Cells to Chemotherapeutic Treatment Mol. Pharmacol., September 1, 2005; 68(3): 779 - 786. [Abstract] [Full Text] [PDF]

				Z.-Y. Xu, M. Loignon, F.-Y. Han, L. Panasci, and R. Aloyz Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced Apoptosis J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 495 - 505. [Abstract] [Full Text] [PDF]

				R. Aloyz, Z.-Y. Xu, V. Bello, J. Bergeron, F.-Y. Han, Y. Yan, A. Malapetsa, M. A. Alaoui-Jamali, A. M. V. Duncan, and L. Panasci Regulation of Cisplatin Resistance and Homologous Recombinational Repair by the TFIIH Subunit XPD Cancer Res., October 1, 2002; 62(19): 5457 - 5462. [Abstract] [Full Text] [PDF]

				V. J. Spanswick, C. Craddock, M. Sekhar, P. Mahendra, P. Shankaranarayana, R. G. Hughes, D. Hochhauser, and J. A. Hartley Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma Blood, June 17, 2002; 100(1): 224 - 229. [Abstract] [Full Text] [PDF]

				A. Slupianek, G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, R. Fishel, and T. Skorski Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis Mol. Cell. Biol., June 15, 2002; 22(12): 4189 - 4201. [Abstract] [Full Text] [PDF]

				Z.-M. Wang, Z.-P. Chen, Z.-Y. Xu, G. Christodoulopoulos, V. Bello, G. Mohr, R. Aloyz, and L. C. Panasci In Vitro Evidence for Homologous Recombinational Repair in Resistance to Melphalan J Natl Cancer Inst, October 3, 2001; 93(19): 1473 - 1478. [Abstract] [Full Text] [PDF]

				L. Panasci, J.-P. Paiement, G. Christodoulopoulos, A. Belenkov, A. Malapetsa, and R. Aloyz Chlorambucil Drug Resistance in Chronic Lymphocytic Leukemia: The Emerging Role of DNA Repair Clin. Cancer Res., March 1, 2001; 7(3): 454 - 461. [Abstract] [Full Text]